Profits From Legal Cannabis Sales Projected to Rise

Wednesday, November 29, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

FinancialBuzz.com News Commentary

NEW YORK, November 29, 2017 /PRNewswire/ --

According to Arcview

Market Research, the regulated cannabis sales in North American totaled $6.7 billion in 2016 and are expected to grow at a compound annual growth rate of 25 percent to an estimated $20.2 billion
by 2021. The demand of cannabis from legal markets is expected to increase as more states legalized products for either recreational or medical use. Consumers in North America spent over $53 billion in the legal and illegal cannabis markets combined in 2016. While only $6.7 billion came from the legal market. Global Payout, Inc. (OTC: GOHE), Easton Pharmaceuticals, Inc. (OTC: EAPH), Lexaria Bioscience Corp. (OTC: LXRP), GB Sciences, Inc. (OTC: GBLX), CV Sciences, Inc. (OTC: CVSI) 

According to another report from Arcview Market Research, the licensed cannabis stores are as profitable as Starbucks stores and the adult-use markets will double the size of the medical market by 2021. Arcview CEO, Troy Dayton, "This report shows that retail cannabis could be as big as the iPhone.  It's clearer than ever that there is a pot of gold at the end of the rainbow for those investors and operators who are willing to deal with the uncertainties and difficulties of current regulations."

Global Payout, Inc. (OTC: GOHE) announced yesterday that, "its majority owned subsidiary, MoneyTrac Technology, Inc. ("MTRAC", the "Company") has established a key strategic partnership with T&T Financial to shore-up and bolster the sales and marketing related services that MTRAC is delivering to many of the underserved businesses in the emerging cannabis industry.

Over the past several weeks, MTRAC has been working in collaboration with additional partners in the financial services sector to lay the groundwork for the banking solutions they intend to offer retailers and suppliers who are operating fully compliant businesses in cannabis. This newly executed partnership with T&T Financial will provide MTRAC with critical sales and marketing support for the banking services and solutions they will be offering to an industry that is currently in dire need of an effective and practical solution to support the massive amount of commerce that currently exists within it.

It is MTRAC's intent to position itself to launch their banking services as soon as possible as it recognizes the need for it amongst businesses will be stronger than ever in 2018 as cannabis becomes recreational in one of the nation's largest economic states, California. And as the Company moves forward with this objective, they will look to establish additional partnerships with companies, such as T&T Financial, whose existing services and solutions can be leveraged by MTRAC to develop and offer the most powerful and effective banking solution available in the industry.

T&T Financial is a full service financial services company located in Anaheim, CA, servicing the needs of business and institutional clients. The principals have a combined 40 years of experience and the firm approaches all solutions with a dynamic approach that the world constantly changes just as its tools and products should adapt to the needs."

Easton Pharmaceuticals, Inc. (OTC: EAPH) is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. Recently, the company announced it is days away from its first equipment delivery to commence operations on its aggregate business with partner 1124123 Ontario Limited following its final payment which completed its $1.3 Million CDN JV agreement towards a 50% property ownership interest and various businesses including a lucrative aggregate business and the cultivation of medical / recreational marijuana for national Canadian market. Acquires construction quotes towards the building of a facility towards medical / recreational marijuana for Canadian market.

Lexaria Bioscience Corp. (OTCQB: LXRP) has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. On November 9, 2017, the company announced it has filed a new patent application with the US Patent and Trademark Office utilizing the Lexaria DehydraTECH[TM] technology for delivery of phosphodiesterase type 5 (PDE5) inhibitors - trade names of existing well-known products include Viagra[TM] (sildenafil) and Cialis[TM] (tadalafil). In its new patent application, Lexaria has named the PDE5 inhibitors from the group consisting of avanafil, lodenafil, mirodenafil, sildenafil (or analogs thereof, for example, actetildenafil, hydroxyacetildenafil, or dimethylsildenafil), tadalafil, vardenafil, udenafil, acetildenafil, and thiomethisosildenafil. In addition, under the new patent application each of these named molecules may be combined with a cannabinoid such as cannabidiol ("CBD"), where the cannabinoid delivered in concert may provide complementary vasodilatory activity beneficial together with the PDE5 inhibitor GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. On October 23, 2017, the company projected sales of $500,000 in October and continued sales of at least $500,000 per month over the next three months. GB Sciences recorded unaudited sales of approximately $320,000 in the three months ended 9/30/17. The company is operating at 200 grow lights, which is only 30% of its expected final capacity after build out is completed. After the final build out, cultivation revenues will continue to increase with a target flower capacity of $18Million annually. The company is expected to open its production facility in late November or early December of 2017. This operating unit should generate additional significant free cash flow from oil over 2018 at a steadily accelerating pace. CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. On November 14, 2017, the company announced it has been named on Deloitte's Technology Fast 500™, an annual ranking of the fastest growing companies in the technology, media, telecommunications, life sciences and energy tech sectors in North America. The Deloitte Technology Fast 500 is based on percentage of revenue growth from fiscal year 2013 to 2016, with CV Sciences growing by 403% during this period. 2017 marks CV Sciences' first year named on the Deloitte's Technology Fast 500™ list. Overall, 2017 Technology Fast 500™ companies achieved revenue growth ranging from 135% to 59,093% from 2013 to 2016, with median growth of 380%.

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For this release, FinancialBuzz.com has been compensated four thousand dollars for financial news dissemination and PR services by a non-affiliate third party for global payout, inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com .

For further information: [email protected] +1-877-601-1879

Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store